Merck KGaA (MRK) Receives Consensus Recommendation of “Buy” from Brokerages
Merck KGaA (FRA:MRK) has received an average recommendation of “Buy” from the twenty-two research firms that are currently covering the stock, Marketbeat Ratings reports. Eleven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is €107.42 ($132.62).
Several equities research analysts have commented on the stock. DZ Bank reiterated a “buy” rating on shares of Merck KGaA in a research note on Monday. JPMorgan Chase & Co. set a €95.00 ($117.28) price objective on shares of Merck KGaA and gave the company a “neutral” rating in a research note on Monday. Kepler Capital Markets set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, January 17th. Sanford C. Bernstein set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, January 17th. Finally, UBS Group reiterated a “buy” rating on shares of Merck KGaA in a research note on Monday, January 15th.
Shares of Merck KGaA (MRK) opened at €81.96 ($101.19) on Tuesday. The company has a market cap of $10,480.00 and a PE ratio of 19.19. Merck KGaA has a one year low of €80.50 ($99.38) and a one year high of €115.00 ($141.98).
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.